MiNK Therapeutics, Inc. INKT
9.34 USD -0.19 (-1.99%)
At closeNov 13, 2026, 4:00 PM EST
9.34 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
9.00 Day range 9.68
8.56 52-week range 14.21
- YTD
- -16.23%
- 1 year
- -29.35%
News
seekingalpha.com MiNK Therapeutics, Inc. (INKT) Q3 2026 Earnings Call Transcript MiNK Therapeutics, Inc. (INKT) Q3 2026 Earnings Call Transcript
zacks.com MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates MiNK Therapeutics, Inc. (INKT) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.65 per share a year ago.
marketbeat.com What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call MiNK Therapeutics NASDAQ: INKT has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with…
benzinga.com MiNK Therapeutics Q3 2026 Earnings Call Transcript MiNK Therapeutics (NASDAQ:INKT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com MiNK Therapeutics Q3 EPS $(0.50) Beats $(0.66) Estimate MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.66) by 24.24 percent. This is a 23.08 percent increase over losses of…
globenewswire.com MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering unmodified, off-the-shelf allogeneic invariant natural killer…- benzinga.com MiNK Therapeutics Presents Preclinical Cancer Data For iNKT Cell Therapy Platform At SITC 2026 Colorectal cancer: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing,…
benzinga.com HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38 HC Wainwright & Co. analyst Matthew Keller assumes MiNK Therapeutics (NASDAQ:INKT) with a Buy rating and announces Price Target of $38.
benzinga.com MiNK Therapeutics To Hold Webcast On Nov. 11 To Review Financial Results, Offer Update On Its Clinical Development Of AgenT-797 MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today…
benzinga.com B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50 B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.